Our Financials

Breast Cancer Trials has increased investment in the research program by approximately 8% each year for the last five years, as we continue to open important clinical trials that aim to improve treatments and save lives.

Breast Cancer Trials generated gross fundraising income of $5.287m for the year, which is an increase of $0.136m from the prior year, despite the continued limitations imposed by COVID 19. Breast Cancer Trials (BCT) recorded an operating deficit for the year ended 31 March 2022 of $0.955m. There was operating income of $11.994m and operating expenses of $12.949m.

There was an increase in operating expenses of 6% over the prior year, principally due to increased activity in the research program. There was total Investment income for the year of $2.199m, which represented an annual return in its investments of 5.9%.It is forecast that BCT will need reserves of $18.648m (net of external cost recoveries) to meet the committed expenses of its approved research program.